This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by MergersUS Inc. or any other third party regardless of whether such security, product or service is referenced in this website. Furthermore, nothing in this website is intended to provide tax, legal, or investment advice and nothing in this website should be construed as a recommendation to buy, sell, or hold any investment or security or to engage in any investment strategy or transaction.MergersCorp M&A International franchising program is not offered to individuals or entities located in the United States.
The franchising program is offered by MergersUK Limited a UK Company with registered office at 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom.
Biotech business with an excellent safety record of more than 2500 clinical treatments. Company designs, manufactures, and markets affinity blood filtration products. A new and highly innovative hemofiltration device that uses patented and proprietary biomimetic technology to quickly remove bacteria, fungi, bacterial toxins, viruses, proinflammatory cytokines, and sepsis mediators from a patient who is afflicted with bloodstream infection.
Investment Appeal
Millions of patients affected globally sepsis market north of 30 million cases each year.
Other applications of this technology may be used as a countermeasure for bioweapons attack (COVID), PDAC cancer, to prevent the side effects of the use of ECMO and cardiopulmonary bypass in diagnostics, blood banking, and bioprocessing.
Just 10x trailing net income could value the company up to $40 Billion by the end of 2028.
Biotech business with an excellent safety record of more than 2500 clinical treatments. Company designs, manufactures, and markets affinity blood filtration products. A new and highly innovative hemofiltration device that uses patented and proprietary biomimetic technology to quickly remove bacteria, fungi, bacterial toxins, viruses, proinflammatory cytokines, and sepsis mediators from a patient who is afflicted with bloodstream infection.
Investment Appeal
Millions of patients affected globally sepsis market north of 30 million cases each year.
Other applications of this technology may be used as a countermeasure for bioweapons attack (COVID), PDAC cancer, to prevent the side effects of the use of ECMO and cardiopulmonary bypass in diagnostics, blood banking, and bioprocessing.
Just 10x trailing net income could value the company up to $40 Billion by the end of 2028.
Description
Biotech business with an excellent safety record of more than 2500 clinical treatments. Company designs, manufactures, and markets affinity blood filtration products. A new and highly innovative hemofiltration device that uses patented and proprietary biomimetic technology to quickly remove bacteria, fungi, bacterial toxins, viruses, proinflammatory cytokines, and sepsis mediators from a patient who is afflicted with bloodstream infection.
Investment Appeal
Millions of patients affected globally sepsis market north of 30 million cases each year.
Other applications of this technology may be used as a countermeasure for bioweapons attack (COVID), PDAC cancer, to prevent the side effects of the use of ECMO and cardiopulmonary bypass in diagnostics, blood banking, and bioprocessing.
Just 10x trailing net income could value the company up to $40 Billion by the end of 2028.
Growth Opportunity
Strong Management
Gross Profit Margins >85%
Basic Details
Target Price:
TBA
Business ID:
L#20240619
Country
United States
Detail
Similar Businesses
Published on February 23, 2024 at 7:26 pm. Updated on February 23, 2024 at 7:32 pm
40-Year-Old MENA Pharmaceutical Manufacturing Company
$45,000,000
Pharma
Historical Pharma Manufacturing Business
$1,050,000,000
Pharma
40 Year Old Rx-pharma Manufacturing Business
$12,000,000
Manufacturing, Pharma
40 Year Old Pharmaceutical Manufacturing Business
$40,000,000
Manufacturing, Pharma
20-Year Old Pharmaceutical South American Brand
$11,500,000
Manufacturing, Pharma
PREVIOUS PROPERTY
20-Year-Old Swiss Operating Broker-Dealer with FINMA Licence
NEXT PROPERTY
3x 28MW + 31MW + 31MW Wind Power Plants Pipeline